Veracyte completes C2i acquisition for up to $95M stock; C2i had $36M loss, $78.6M debt

VERACYTE, INC.

Acquisition closed Feb 5, 2024; total consideration up to $95M in Veracyte common stock.
C2i 2023 revenue $456k, net loss $36.0M, R&D expense $17.9M, operating loss $21.9M.
C2i had $78.6M in convertible promissory notes, $18.8M cash, $76.1M accumulated deficit as of Dec 31, 2023.
Veracyte files audited C2i financials and unaudited pro forma combined statements to satisfy SEC requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.